Skye Bioscience Tests Higher Nimacimab Doses to Optimize Obesity Drug Combination
Event summary
- Skye Bioscience begins Part C expansion study of nimacimab, testing 400 mg and 600 mg IV doses to assess safety and pharmacokinetics over 16 weeks.
- First patient treated in April 2026, with topline data expected in Q4 2026.
- Study aims to inform Phase 2b dose selection for GLP-1 combination development.
- Nimacimab demonstrated 22.3% mean weight loss in combination with semaglutide in Phase 2a trial.
- FDA provided written feedback on proposed Phase 2b trial design.
The big picture
Skye Bioscience is advancing its peripherally restricted CB1 inhibitor, nimacimab, with a focus on optimizing dosing for combination therapy with GLP-1 agonists like semaglutide. The company aims to address the growing demand for more effective obesity treatments by leveraging translational data to refine its clinical strategy. The success of this approach could set a precedent for developing combination therapies that target multiple metabolic pathways without adding neuropsychiatric side effects.
What we're watching
- Dose Optimization
- Whether higher nimacimab doses will achieve the expected pharmacokinetic step-up while maintaining a favorable safety profile.
- Regulatory Pathway
- The impact of FDA feedback on the final Phase 2b trial design and timing.
- Commercial Strategy
- How Skye will position nimacimab as an orthogonal add-on therapy for patients who have plateaued on GLP-1 treatments.
Related topics